Limits...
Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.

Leung EY, Askarian-Amiri M, Finlay GJ, Rewcastle GW, Baguley BC - PLoS ONE (2015)

Bottom Line: We then carried out combination studies with four everolimus resistant triple-negative breast cancer cell lines, and found an unexpectedly high degree of synergy between everolimus and the other inhibitors tested.The level of potentiation of everolimus inhibitory activity (measured by IC50 values) was found to be cell line-specific for all the kinase inhibitors tested.The results suggest that judicious combination of mTOR inhibitors with different modes of action could have beneficial effects in the treatment of breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Auckland Cancer Society Research Centre, University of Auckland, Grafton, Auckland, New Zealand; Department of Molecular Medicine and Pathology, University of Auckland, Grafton, Auckland, New Zealand.

ABSTRACT
The mammalian target of rapamycin (mTOR), a vital component of signaling pathways involving PI3K/AKT, is an attractive therapeutic target in breast cancer. Everolimus, an allosteric mTOR inhibitor that inhibits the mTOR functional complex mTORC1, is approved for treatment of estrogen receptor positive (ER+) breast cancer. Other mTOR inhibitors show interesting differences in target specificities: BEZ235 and GSK2126458 are ATP competitive mTOR inhibitors targeting both PI3K and mTORC1/2; AZD8055, AZD2014 and KU-0063794 are ATP competitive mTOR inhibitors targeting both mTORC1 and mTORC2; and GDC-0941 is a pan-PI3K inhibitor. We have addressed the question of whether mTOR inhibitors may be more effective in combination than singly in inhibiting the proliferation of breast cancer cells. We selected a panel of 30 human breast cancer cell lines that included ER and PR positive, HER2 over-expressing, and "triple negative" variants, and determined whether signaling pathway utilization was related to drug-induced inhibition of proliferation. A significant correlation (p = 0.005) was found between everolimus IC50 values and p70S6K phosphorylation, but not with AKT or ERK phosphorylation, consistent with the mTOR pathway being a principal target. We then carried out combination studies with four everolimus resistant triple-negative breast cancer cell lines, and found an unexpectedly high degree of synergy between everolimus and the other inhibitors tested. The level of potentiation of everolimus inhibitory activity (measured by IC50 values) was found to be cell line-specific for all the kinase inhibitors tested. The results suggest that judicious combination of mTOR inhibitors with different modes of action could have beneficial effects in the treatment of breast cancer.

No MeSH data available.


Related in: MedlinePlus

Growth sensitivity to the combination of everolimus and kinase inhibitors.Synergy, positive Bliss value, was observed for all drugs tested. Bliss = 0 indicates the combination is additive; Bliss > 0 indicates the percentage increase in maximal inhibition above additivity (synergy); and Bliss < 0 indicates the percentage increase in maximal inhibition below additivity (antagonism).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4492962&req=5

pone.0131400.g009: Growth sensitivity to the combination of everolimus and kinase inhibitors.Synergy, positive Bliss value, was observed for all drugs tested. Bliss = 0 indicates the combination is additive; Bliss > 0 indicates the percentage increase in maximal inhibition above additivity (synergy); and Bliss < 0 indicates the percentage increase in maximal inhibition below additivity (antagonism).

Mentions: Although synergy was observed in all cell lines tested, the level of synergy of drug combination (everolimus and BEZ235, GSK2126458, AZD8055, AZD2014, KU-0063794 or GDC-0941) (Table 1; Fig 9) was found to be cell line specific. Significant differences in drug combination effects (Holm-Sidak method) were observed in BT20 (p < 0.01), HCC1143 (p = 0.01) and MDA-MB-231 (p = 0.023) using multiple comparisons and MDA-MB-436 as the control group.


Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.

Leung EY, Askarian-Amiri M, Finlay GJ, Rewcastle GW, Baguley BC - PLoS ONE (2015)

Growth sensitivity to the combination of everolimus and kinase inhibitors.Synergy, positive Bliss value, was observed for all drugs tested. Bliss = 0 indicates the combination is additive; Bliss > 0 indicates the percentage increase in maximal inhibition above additivity (synergy); and Bliss < 0 indicates the percentage increase in maximal inhibition below additivity (antagonism).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4492962&req=5

pone.0131400.g009: Growth sensitivity to the combination of everolimus and kinase inhibitors.Synergy, positive Bliss value, was observed for all drugs tested. Bliss = 0 indicates the combination is additive; Bliss > 0 indicates the percentage increase in maximal inhibition above additivity (synergy); and Bliss < 0 indicates the percentage increase in maximal inhibition below additivity (antagonism).
Mentions: Although synergy was observed in all cell lines tested, the level of synergy of drug combination (everolimus and BEZ235, GSK2126458, AZD8055, AZD2014, KU-0063794 or GDC-0941) (Table 1; Fig 9) was found to be cell line specific. Significant differences in drug combination effects (Holm-Sidak method) were observed in BT20 (p < 0.01), HCC1143 (p = 0.01) and MDA-MB-231 (p = 0.023) using multiple comparisons and MDA-MB-436 as the control group.

Bottom Line: We then carried out combination studies with four everolimus resistant triple-negative breast cancer cell lines, and found an unexpectedly high degree of synergy between everolimus and the other inhibitors tested.The level of potentiation of everolimus inhibitory activity (measured by IC50 values) was found to be cell line-specific for all the kinase inhibitors tested.The results suggest that judicious combination of mTOR inhibitors with different modes of action could have beneficial effects in the treatment of breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Auckland Cancer Society Research Centre, University of Auckland, Grafton, Auckland, New Zealand; Department of Molecular Medicine and Pathology, University of Auckland, Grafton, Auckland, New Zealand.

ABSTRACT
The mammalian target of rapamycin (mTOR), a vital component of signaling pathways involving PI3K/AKT, is an attractive therapeutic target in breast cancer. Everolimus, an allosteric mTOR inhibitor that inhibits the mTOR functional complex mTORC1, is approved for treatment of estrogen receptor positive (ER+) breast cancer. Other mTOR inhibitors show interesting differences in target specificities: BEZ235 and GSK2126458 are ATP competitive mTOR inhibitors targeting both PI3K and mTORC1/2; AZD8055, AZD2014 and KU-0063794 are ATP competitive mTOR inhibitors targeting both mTORC1 and mTORC2; and GDC-0941 is a pan-PI3K inhibitor. We have addressed the question of whether mTOR inhibitors may be more effective in combination than singly in inhibiting the proliferation of breast cancer cells. We selected a panel of 30 human breast cancer cell lines that included ER and PR positive, HER2 over-expressing, and "triple negative" variants, and determined whether signaling pathway utilization was related to drug-induced inhibition of proliferation. A significant correlation (p = 0.005) was found between everolimus IC50 values and p70S6K phosphorylation, but not with AKT or ERK phosphorylation, consistent with the mTOR pathway being a principal target. We then carried out combination studies with four everolimus resistant triple-negative breast cancer cell lines, and found an unexpectedly high degree of synergy between everolimus and the other inhibitors tested. The level of potentiation of everolimus inhibitory activity (measured by IC50 values) was found to be cell line-specific for all the kinase inhibitors tested. The results suggest that judicious combination of mTOR inhibitors with different modes of action could have beneficial effects in the treatment of breast cancer.

No MeSH data available.


Related in: MedlinePlus